Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
HQ Slovenia · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products not yet catalogued.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
No adverse media involving Better found in HSH's search of the last 24 months.
No data breaches, cyber incidents or regulator action involving Better found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
No recalls, safety notices or clinical safety incidents involving Better or its Better Meds ePMA product found in HSH's search of the last 24 months.
Jun 2026: Powys Teaching Health Board went live with Better's ePMA, following other NHS Wales wins including Velindre University NHS Trust (Dec 2025) and Aneurin Bevan University Health Board (Feb 2025).
No competitors linked yet.